Pharmaniaga classified under PN17


PETALING JAYA: Pharmaniaga Bhd has been classified as an affected listed issuer under Practice Note 17 (PN17) of the Main Market Listing Requirements of Bursa Malaysia.

In a filing with the stock exchange yesterday, the pharmaceutical company said it had triggered the PN17 criteria pursuant to its audited consolidated financial statements for the period ended Dec 31, 2022.

Get 20% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 11.12/month

Billed as RM 11.12 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 9.87/month

Billed as RM 118.40 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

Bank Indonesia to intervene in forex, bond markets to stabilise rupiah, official says
Singapore's retrenchment rate at highest level since 2020 in Q2 this year, ministry says
Gold slips as investors focus on Middle East, rate outlook
Oil prices slide on hopes of diplomacy in Iran war
Amfirst REIT unit holders approve RM331mil Menara AmBank disposal
Asean’s next integration phase could draw on NIMP 2030 principles
Tanjong Malim Hi-Tech Park with RM1.4bil GDV targeted for completion by 3Q29
Yuan hits fresh multi-year peak as PBOC eases curb ahead of Trump-Xi summit
Electric cars to play future role in power supply
Asian tech stocks rise on AI optimism; Trump-Xi meeting in focus

Others Also Read